Nebulized tobramycin in patients with chronic respiratory infections during clinical evolution of Wegener's Granulomatosis

C. Terzano, A. E. Taurino, V. Peona

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Abstract.- Aminoglycosides are effective against Pseudomonas aeruginosa but with intravenous administration there are only very low concentrations achieved in sputum; therefore in order to obtain therapeutic levels in patients with endobronchial infections should be administered high doses with increased likelihood to produce both nephrotoxic and ototoxic effects. Direct aerosol delivery of aminoglycosides to the lower respiratory tract has the advantage to achieve high antibiotic sputum concentrations in the infected area with reduced risk of systemic toxic reactions because of minimal absorption into the circulation. Nowadays, except for patients suffering from cystic fibrosis and bronchiectasis, the administration of antibiotics through inhalers is not very much in use. The aim of this study was to administer nebulized tobramycin in chronic respiratory infections developed during the evolution of Wegener's Granulomatosis in order to obtain data concerning the safety and efficacy of inhaled aminoglycosides. The results obtained underlined an improvement in FEV 1, FEF 72 and PaO 2. The aerosolized tobramycin administered in 300 mg doses three times per day for four weeks, showed itself to be effective and safe, not causing any undesirable clinical or microbiological side-effects. Moreover, a long term treatment has been shown to control the Pseudomonas aeruginosa infection on the bronchial system in Wegener's granulomatosis and reduce the frequency of exacerbations in chronic patients.

Original languageEnglish
Pages (from-to)131-138
Number of pages8
JournalEuropean Review for Medical and Pharmacological Sciences
Volume5
Issue number4
Publication statusPublished - 2002

Fingerprint

Granulomatosis with Polyangiitis
Tobramycin
Aminoglycosides
Respiratory Tract Infections
Sputum
Pseudomonas aeruginosa
Anti-Bacterial Agents
Pseudomonas Infections
Bronchiectasis
Poisons
Nebulizers and Vaporizers
Aerosols
Cystic Fibrosis
Intravenous Administration
Respiratory System
Safety
Therapeutics
Infection

Keywords

  • Aerosol
  • Pseudomonas aeruginosa
  • Tobramycin
  • Wegener' Granulomatosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{a122b43162534e54b8fab2c950b78282,
title = "Nebulized tobramycin in patients with chronic respiratory infections during clinical evolution of Wegener's Granulomatosis",
abstract = "Abstract.- Aminoglycosides are effective against Pseudomonas aeruginosa but with intravenous administration there are only very low concentrations achieved in sputum; therefore in order to obtain therapeutic levels in patients with endobronchial infections should be administered high doses with increased likelihood to produce both nephrotoxic and ototoxic effects. Direct aerosol delivery of aminoglycosides to the lower respiratory tract has the advantage to achieve high antibiotic sputum concentrations in the infected area with reduced risk of systemic toxic reactions because of minimal absorption into the circulation. Nowadays, except for patients suffering from cystic fibrosis and bronchiectasis, the administration of antibiotics through inhalers is not very much in use. The aim of this study was to administer nebulized tobramycin in chronic respiratory infections developed during the evolution of Wegener's Granulomatosis in order to obtain data concerning the safety and efficacy of inhaled aminoglycosides. The results obtained underlined an improvement in FEV 1, FEF 72 and PaO 2. The aerosolized tobramycin administered in 300 mg doses three times per day for four weeks, showed itself to be effective and safe, not causing any undesirable clinical or microbiological side-effects. Moreover, a long term treatment has been shown to control the Pseudomonas aeruginosa infection on the bronchial system in Wegener's granulomatosis and reduce the frequency of exacerbations in chronic patients.",
keywords = "Aerosol, Pseudomonas aeruginosa, Tobramycin, Wegener' Granulomatosis",
author = "C. Terzano and Taurino, {A. E.} and V. Peona",
year = "2002",
language = "English",
volume = "5",
pages = "131--138",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "4",

}

TY - JOUR

T1 - Nebulized tobramycin in patients with chronic respiratory infections during clinical evolution of Wegener's Granulomatosis

AU - Terzano, C.

AU - Taurino, A. E.

AU - Peona, V.

PY - 2002

Y1 - 2002

N2 - Abstract.- Aminoglycosides are effective against Pseudomonas aeruginosa but with intravenous administration there are only very low concentrations achieved in sputum; therefore in order to obtain therapeutic levels in patients with endobronchial infections should be administered high doses with increased likelihood to produce both nephrotoxic and ototoxic effects. Direct aerosol delivery of aminoglycosides to the lower respiratory tract has the advantage to achieve high antibiotic sputum concentrations in the infected area with reduced risk of systemic toxic reactions because of minimal absorption into the circulation. Nowadays, except for patients suffering from cystic fibrosis and bronchiectasis, the administration of antibiotics through inhalers is not very much in use. The aim of this study was to administer nebulized tobramycin in chronic respiratory infections developed during the evolution of Wegener's Granulomatosis in order to obtain data concerning the safety and efficacy of inhaled aminoglycosides. The results obtained underlined an improvement in FEV 1, FEF 72 and PaO 2. The aerosolized tobramycin administered in 300 mg doses three times per day for four weeks, showed itself to be effective and safe, not causing any undesirable clinical or microbiological side-effects. Moreover, a long term treatment has been shown to control the Pseudomonas aeruginosa infection on the bronchial system in Wegener's granulomatosis and reduce the frequency of exacerbations in chronic patients.

AB - Abstract.- Aminoglycosides are effective against Pseudomonas aeruginosa but with intravenous administration there are only very low concentrations achieved in sputum; therefore in order to obtain therapeutic levels in patients with endobronchial infections should be administered high doses with increased likelihood to produce both nephrotoxic and ototoxic effects. Direct aerosol delivery of aminoglycosides to the lower respiratory tract has the advantage to achieve high antibiotic sputum concentrations in the infected area with reduced risk of systemic toxic reactions because of minimal absorption into the circulation. Nowadays, except for patients suffering from cystic fibrosis and bronchiectasis, the administration of antibiotics through inhalers is not very much in use. The aim of this study was to administer nebulized tobramycin in chronic respiratory infections developed during the evolution of Wegener's Granulomatosis in order to obtain data concerning the safety and efficacy of inhaled aminoglycosides. The results obtained underlined an improvement in FEV 1, FEF 72 and PaO 2. The aerosolized tobramycin administered in 300 mg doses three times per day for four weeks, showed itself to be effective and safe, not causing any undesirable clinical or microbiological side-effects. Moreover, a long term treatment has been shown to control the Pseudomonas aeruginosa infection on the bronchial system in Wegener's granulomatosis and reduce the frequency of exacerbations in chronic patients.

KW - Aerosol

KW - Pseudomonas aeruginosa

KW - Tobramycin

KW - Wegener' Granulomatosis

UR - http://www.scopus.com/inward/record.url?scp=0036265278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036265278&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 131

EP - 138

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 4

ER -